Search ↗

Comparison

Liraglutide vs Tirzepatide

Both are GLP-1 & incretins, so the meaningful differences are in kinetics, evidence and regulatory status.

Liraglutide Tirzepatide
Class GLP-1 & incretins GLP-1 & incretins
Evidence Regulator approved Regulator approved
Human trials ~70 ~60
Half-life ~13 hours ~5 days
Reported range 600 mcg - 3 mg 2.5-15 mg
Frequency Once daily, titrated weekly Once weekly, titrated over 20+ weeks
Routes Subcutaneous Subcutaneous
FDA approved Yes Yes
Research use only No No
Banned in sport No No
Studied for Type 2 diabetes, Chronic weight management Type 2 diabetes, Chronic weight management, Obstructive sleep apnoea with obesity
Reported side effects Nausea, Diarrhoea, Vomiting, Headache, Injection-site reactions Nausea, Diarrhoea, Vomiting, Constipation, Dyspepsia, Injection-site reactions

Liraglutide

Liraglutide is a GLP-1 analog with 97% homology to the native hormone, modified by a C16 palmitic acid chain attached via a glutamic acid spacer. Albumin binding and self-association slow absorption enough for once-daily dosing, but not weekly. Its mechanism is otherwise the same as semaglutide: glucose-dependent insulinotropic action, glucagon suppression, delayed gastric emptying and central appetite reduction. Weight loss in the SCALE programme averaged around 8%, materially below the newer agents.

Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide that agonises both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, a combination sometimes called a twincretin. GIP receptor activity appears to add to the metabolic effect through adipose tissue and central pathways, and may attenuate some GLP-1-related nausea. A C20 fatty diacid moiety confers albumin binding and weekly dosing. The SURMOUNT programme reported mean weight reductions above 20% at the highest dose, and SURMOUNT-5 showed superiority over semaglutide directly.

Liraglutide vs Tirzepatide: common questions

What is the difference between Liraglutide and Tirzepatide?

Both are GLP-1 & incretins. Liraglutide: The first-generation daily GLP-1 agonist, largely superseded by weekly agents but still widely prescribed. Tirzepatide: A dual GIP and GLP-1 receptor agonist that produced greater weight loss than semaglutide in head-to-head trial data.

Which has stronger evidence, Liraglutide or Tirzepatide?

They sit at the same evidence level: regulator approved. Liraglutide has about 70 human studies and Tirzepatide about 60.

Are Liraglutide and Tirzepatide FDA approved?

Both are FDA approved. Liraglutide: Type 2 diabetes mellitus (Victoza); Reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (Victoza, 2017); Type 2 diabetes in children aged 10 and older (Victoza, 2019); Chronic weight management (Saxenda); Chronic weight management in adolescents aged 12 and older with obesity (Saxenda, 2020). Tirzepatide: Type 2 diabetes mellitus (Mounjaro); Chronic weight management (Zepbound); Moderate to severe obstructive sleep apnoea in adults with obesity.

References

Regulatory and primary sources

  1. PubChem compound record (CID 16134956) ↗ · structure, identifiers, synonyms
  2. DailyMed: FDA-approved labeling for Liraglutide ↗ · indications, dosing, warnings as approved
  3. FDA Drugs@FDA database ↗ · approval history
  4. CAS Registry Number 204656-20-2 ↗ · chemical identity
  5. PubChem compound record (CID 156588324) ↗ · structure, identifiers, synonyms
  6. DailyMed: FDA-approved labeling for Tirzepatide ↗ · indications, dosing, warnings as approved
  7. FDA Drugs@FDA database ↗ · approval history
  8. CAS Registry Number 2023788-19-2 ↗ · chemical identity

Published literature

  1. Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA 2022.PubMed 35015037 · doi:10.1001/jama.2021.23619
  2. Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med 2016.PubMed 27295427 · doi:10.1056/NEJMoa1603827
  3. Fox CK, Barrientos-Pérez M, Bomberg EM, et al.. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.N Engl J Med 2025.PubMed 39258838 · doi:10.1056/NEJMoa2407379
  4. Pi-Sunyer X, Astrup A, Fujioka K, et al.. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.N Engl J Med 2015.PubMed 26132939 · doi:10.1056/NEJMoa1411892
  5. Lundgren JR, Janus C, Jensen SBK, et al.. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.N Engl J Med 2021.PubMed 33951361 · doi:10.1056/NEJMoa2028198
  6. Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.Lancet 2016.PubMed 26608256 · doi:10.1016/S0140-6736(15)00803-X
  7. Kelly AS, Auerbach P, Barrientos-Perez M, et al.. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.N Engl J Med 2020.PubMed 32233338 · doi:10.1056/NEJMoa1916038
  8. Capehorn MS, Catarig AM, Furberg JK, et al.. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).Diabetes Metab 2020.PubMed 31539622 · doi:10.1016/j.diabet.2019.101117
  9. Jastreboff AM, le Roux CW, Stefanski A, et al.. Tirzepatide for Obesity Treatment and Diabetes Prevention.N Engl J Med 2025.PubMed 39536238 · doi:10.1056/NEJMoa2410819
  10. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med 2022.PubMed 35658024 · doi:10.1056/NEJMoa2206038
  11. Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.JAMA 2024.PubMed 38078870 · doi:10.1001/jama.2023.24945
  12. Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.N Engl J Med 2024.PubMed 38912654 · doi:10.1056/NEJMoa2404881
  13. Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med 2025.PubMed 39555826 · doi:10.1056/NEJMoa2410027
  14. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
  15. Look M, Dunn JP, Kushner RF, et al.. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes Obes Metab 2025.PubMed 39996356 · doi:10.1111/dom.16275
  16. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med 2021.PubMed 34170647 · doi:10.1056/NEJMoa2107519

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.